Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Cisplatin Dose Sequencing
Cisplatin should be administered 30 minutes after pemetrexed.
Dosing Sequence Rationale
Pemetrexed is a pyrimidine and purine inhibitor and therefore it may influence cisplatin in the formation or the repair of formed adducts. Given that both chemotherapeutic agents are cell-cycle specific, their effect on the cell cycle can alter their individual cytotoxic effects.2,3
The interaction of pemetrexed and cisplatin may be dependent on the sequence of drug exposure, as well as on the tumor type. An in vitro study demonstrated that the simultaneous exposure to pemetrexed and cisplatin produced antagonistic effects in A549 lung, MCF7 breast and PA1 ovarian carcinoma cells, but additive effects in WiDr colon carcinoma cells.4
In contrast, the same study demonstrated that pemetrexed followed by cisplatin produced synergistic effects in MCF7 cells, greater than additive effects in A549 and PA1 cells, and additive effects in WiDr cells. Cisplatin followed by pemetrexed produced antagonistic effects in A549, MCF7, and PA1 cells and additive effects in WiDr cells. The investigators concluded that the administration of pemetrexed prior to cisplatin would be the preferred sequence.4
Dosing, hydration and anti-emetic treatment
The recommended dose of pemetrexed is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle.10
Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (see also cisplatin Summary of Product Characteristics for specific dosing advice).10
Pemetrexed in combination with cisplatin is indicated
- for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology, and
- for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.10
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Jäckel M, Köpf-Maier P. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol. 1991;27(6):464-471. http://dx.doi.org/10.1007/BF00685161
3Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol. 1997;39(6):521-531. http://dx.doi.org/10.1007/s002800050608
4Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res. 2006;16(2):85-95. https://doi.org/10.3727/000000006783981215
5Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136
6Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non–small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11(2):690-696. http://clincancerres.aacrjournals.org/cgi/content/abstract/11/2/690
7Tachihara M, Dokuni R, Okuno K, et al. Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer. Thorac Cancer. 2020;11(9):2536-2541. https://doi.org/10.1111/1759-7714.13567
8Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. J Clin Oncol. 2013;31(23):2895-2902. http://dx.doi.org/10.1200/JCO.2012.47.1102
9Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. http://dx.doi.org/10.1056/NEJMoa1801005
10Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands
Date of Last Review: 28 April 2021